Last reviewed · How we verify
Azopt 1%
Azopt is a topical carbonic anhydrase inhibitor that reduces intraocular pressure by decreasing aqueous humor production in the eye.
Azopt is a topical carbonic anhydrase inhibitor that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | Azopt 1% |
|---|---|
| Also known as | brinzolamide |
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase II |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Brinzolamide, the active ingredient in Azopt, inhibits carbonic anhydrase II in the ciliary body of the eye, which reduces the secretion of aqueous humor and thereby lowers intraocular pressure. This mechanism makes it effective for treating glaucoma and ocular hypertension by reducing fluid production rather than increasing fluid drainage.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Blurred vision
- Ocular discomfort
- Taste perversion
- Conjunctivitis
Key clinical trials
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt (PHASE3)
- Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt (PHASE1, PHASE2)
- To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- Effect of Lowering IOP in Glaucoma Suspects With HM (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azopt 1% CI brief — competitive landscape report
- Azopt 1% updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI